Worth a Shot? Evidence-Based Approach to Prescribing LAI Antipsychotic Medications-View Presentation

Video Transcription

Video Summary

This webinar, led by Dr. Leon Raven and hosted by Donna Rowland, explores the evidence-based use of long-acting injectable (LAI) antipsychotic medications in treating schizophrenia. Dr. Raven reviews APA guidelines, which recommend offering LAIs as a treatment option from diagnosis, especially for patients with poor adherence. Studies show significant challenges in accurately assessing oral medication adherence, with up to 57% of patients non-adherent despite self- and physician-reports suggesting otherwise.<br /><br />Data from observational studies and randomized trials indicate that LAIs reduce risks of hospitalization, treatment discontinuation, violence, and mortality compared to oral antipsychotics. Second-generation LAIs generally outperform first-generation ones, showing better adherence, fewer hospitalizations, less polypharmacy, and lower healthcare costs. LAIs also demonstrate benefits in forensic settings and improve survival times post-discharge. Early initiation of LAIs after diagnosis is linked to better outcomes.<br /><br />The webinar highlights issues such as inconsistent plasma drug levels with oral medications, the benefit of regular follow-up especially post-discharge, and the development of newer LAI formulations with longer dosing intervals. Despite some unresolved questions about mechanisms and ideal dosing intervals, LAIs are affirmed as a valuable tool in schizophrenia management, providing more consistent drug delivery and improved outcomes over oral antipsychotics.

Keywords

long-acting injectable antipsychotics

schizophrenia treatment

medication adherence

APA guidelines

hospitalization reduction

second-generation LAIs

oral antipsychotics comparison

forensic psychiatry

early LAI initiation